Association Between Screening Behaviors and Lung Cancer Spectrum
A Multicenter, Prospective, Observational Study on the Association Between Real-World Lung Cancer Screening Behaviors and Lung Cancer Disease Spectrum
The goal of this observational study is to describe the clinical epidemiological characteristics and disease spectrum distribution of newly diagnosed primary lung cancer patients in a real-world setting. The main questions it aims to answer are:
What is the current status of lung cancer epidemiology, including age, gender, smoking history, and pathological subtype distribution? How do different lung cancer screening behaviors (e.g., overscreening, underscreening, guideline-concordant, and precision screening) influence the capture rate of the "curative time window" (defined as adenocarcinoma in situ (AIS)/minimally invasive adenocarcinoma (MIA) or pure Ground-Glass Nodules (GGNs) stage)? What are the economic costs and cumulative radiation exposure associated with these different screening patterns? Researchers will compare these screening behavior groups to evaluate the efficacy of the "low-age, low-frequency" screening strategy in capturing early-stage lung cancer.
Participants will be asked to:
Provide their medical history and detailed records of pre-diagnosis lung cancer screening (including CT scan history).
Allow researchers to collect and analyze their clinical, pathological, and radiological data from hospital records and medical databases.
Complete a questionnaire regarding their screening history and health-related behaviors.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Locais de estudo
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Recrutamento
- Fudan University Cancer Center
-
Contato:
- Chen Haiquan, MD
- Número de telefone: 1707 +86-21 64175590
- E-mail: hqchen1@yahoo.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Histologically confirmed primary lung cancer within the past year (surgical or biopsy pathology).
- Patients capable of clearly recalling or providing medical and physical examination history prior to diagnosis.
Exclusion Criteria:
- Recurrent lung cancer or metastatic lung tumors.
- Severe lack of critical clinical data (e.g., inability to provide pathological type or stage).
- Patients with cognitive impairment or severe mental illness who cannot cooperate with the questionnaire.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Epidemiological Characteristics
Prazo: through study completion, an average of 1 year
|
Distribution of age, gender, smoking history, and pathological subtypes.
|
through study completion, an average of 1 year
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Curative Time Window Capture Rate
Prazo: through study completion, an average of 1 year
|
The proportion of tumors captured at the AIS/MIA or pure GGN stage
|
through study completion, an average of 1 year
|
|
Socioeconomic Indicators
Prazo: through study completion, an average of 1 year
|
This measure assesses the total direct medical costs.
Data are collected through a combination of hospital electronic medical records (EMR) and a structured patient questionnaire.
Costs include pre-diagnosis examination expenses (e.g., CT scans, consultations) and post-diagnosis treatment expenses (e.g., surgery, hospitalization, systemic therapy), calculated based on standardized clinical billing data.
|
through study completion, an average of 1 year
|
|
Cumulative Radiation Dose
Prazo: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
|
Screening Efficacy
Prazo: through study completion, an average of 1 year
|
This measure evaluates the efficacy of screening behaviors in detecting early-stage lung cancer.
Data are derived from hospital clinical databases and a structured patient questionnaire.
Key parameters include the frequency of pre-diagnosis CT scans, age at first screening, and pathological stage at diagnosis.
The association is assessed using correlation analysis and logistic regression models to compare the capture rate of the "curative time window" (AIS/MIA/pure GGN) across different screening groups.
|
through study completion, an average of 1 year
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ECTOP-1038
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .